OptiMedica Corp.’s Pascal Photocoagulator is now available for international sale, because of the company’s recent ISO 13485 certification and CE Mark approval.
OptiMedica Corp.’s Pascal Photocoagulator is now available for international sale, because of the company’s recent ISO 13485 certification and CE Mark approval.
The first Pascal systems outside of the United States will be placed at key practices in Japan and Europe.
The company immediately will begin working with leading international ophthalmologists to establish a new standard of care in the treatment of retinal diseases.
Understanding the biological causes and cell types that lead to one of the leading causes of irreversible blindness worldwide could benefit treatment in patients
Aerie Pharmaceuticals doses first participant in COMET-2 study of dry eye candidate
Technology, people key to improving health outcomes, driving revenue